Clinical Trials Directory

Trials / Completed

CompletedNCT05218863

Incidence, Diagnosis, Management and Outcome of Acute Mesenteric Ischemia

Incidence, Diagnosis, Management and Outcome of Acute Mesenteric Ischaemia: a Prospective, Multicentre Observational Study

Status
Completed
Phase
Study type
Observational
Enrollment
709 (actual)
Sponsor
University of Tartu · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is a prospective, multicentre observational study screening all adult patients admitted to a participating hospital over a 6-month study period (may be adjusted to 4-8 months according to recruitment) and including all patients with suspicion of or confirmed acute mesenteric ischaemia (AMI). Only admission data and hospital mortality outcome will be collected for patients in whom suspicion of AMI is not confirmed. For patients with confirmed AMI full data collection regarding diagnostics, management and long-term outcome is required. Investigators aim to recruit 40-50 sites with expected median of 10-20 patients with confirmed AMI per site during the study period (naturally depending on the size of the hospital). The start of the study is planned for Spring 2022. The aim of the study is to identify the incidence of AMI and its different forms in adult hospitalized patients, and to describe patient characteristics (demographic, clinical and laboratory) at baseline, applied diagnostics and management, as well as outcomes in patients with AMI. An additional aim is to compare the baseline characteristics and outcomes of patients with confirmed AMI to those of patients with suspected AMI in whom the diagnosis was not confirmed.

Conditions

Interventions

TypeNameDescription
OTHERNo interventionNo intervention

Timeline

Start date
2022-06-06
Primary completion
2023-04-05
Completion
2023-04-05
First posted
2022-02-01
Last updated
2023-05-31

Locations

3 sites across 2 countries: Estonia, Switzerland

Source: ClinicalTrials.gov record NCT05218863. Inclusion in this directory is not an endorsement.